The portfolio maintains a sizable cost advantage over competitors, priced within the lowest fee quintile among peers.
iShares US Pharmaceuticals ETF IHE
Morningstar’s Analysis IHE
Will IHE outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 79.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 23.49 | 152.9 Mil | Healthcare |
Johnson & Johnson | 22.16 | 144.3 Mil | Healthcare |
Merck & Co Inc | 4.94 | 32.2 Mil | Healthcare |
Pfizer Inc | 4.56 | 29.7 Mil | Healthcare |
Royalty Pharma PLC Class A | 4.53 | 29.5 Mil | Healthcare |
Viatris Inc | 4.44 | 28.9 Mil | Healthcare |
Bristol-Myers Squibb Co | 4.37 | 28.5 Mil | Healthcare |
Catalent Inc | 4.33 | 28.2 Mil | Healthcare |
Zoetis Inc Class A | 4.04 | 26.3 Mil | Healthcare |
Intra-Cellular Therapies Inc | 2.94 | 19.2 Mil | Healthcare |